
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.





























